Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial.
about
HIV-1 integrase inhibitor resistance and its clinical implicationsLong-term efficacy and safety of raltegravir in the management of HIV infection.Statistical methods in recent HIV noninferiority trials: reanalysis of 11 trialsHigh concentration of raltegravir in semen of HIV-infected men: results from a substudy of the EASIER-ANRS 138 trial.Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial.Deficient reporting and interpretation of non-inferiority randomized clinical trials in HIV patients: a systematic review.Extended use of raltegravir in the treatment of HIV-1 infection: optimizing therapySwitch from enfuvirtide to raltegravir lowers plasma concentrations of darunavir and tipranavir: a pharmacokinetic substudy of the EASIER-ANRS 138 trial.Treatment simplification in HIV-infected adults as a strategy to prevent toxicity, improve adherence, quality of life and decrease healthcare costs.Factors That Affect Quality of Life among People Living with HIV Attending an Urban Clinic in Uganda: A Cohort Study.Emerging integrase inhibitor resistance mutations in raltegravir-treated HIV-1-infected patients with low-level viremia.Authentic HIV-1 integrase inhibitors.Modifying Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients.Incidence and risk factors for liver enzymes elevations in highly treatment-experienced patients switching from enfuvirtide to raltegravir: a sub-study of the ANRS-138 EASIER trial.Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 years.Raltegravir: a review of its pharmacokinetics, pharmacology and clinical studies.Novel integrase inhibitors for HIV.Enfuvirtide: from basic investigations to current clinical use.Next-generation integrase inhibitors : where to after raltegravir?Archived HIV-1 DNA resistance mutations to rilpivirine and etravirine in successfully treated HIV-1-infected individuals pre-exposed to efavirenz or nevirapine.Review of integrase strand transfer inhibitors for the treatment of human immunodeficiency virus infection.Inhibiting the HIV integration process: past, present, and the future.Cost-Effectiveness of Antiretroviral Therapy for Multidrug-Resistant HIV: Past, Present, and Future.Decreased PD-1 Expression on CD8 Lymphocyte Subsets and Increase in CD8 Tscm Cells in Children with HIV Receiving Raltegravir.Pharmacokinetic study of raltegravir in HIV-infected patients with end-stage liver disease: the LIVERAL-ANRS 148 study.Efficacy of raltegravir switching strategies in HIV-infected patients with suppressed viraemia according to the genotypic sensitivity score.Impact on health-related quality of life of a switch from enfuvirtide to raltegravir among multidrug-resistant HIV-1-infected patients: a randomized open-label trial (EASIER-ANRS 138).The SWITCHMRK studies: substitution of lopinavir/ritonavir with raltegravir in HIV-positive individuals.Efficacy of antiretroviral therapy switch in HIV-infected patients: a 10-year analysis of the EuResist Cohort.
P2860
Q24628743-1E67528D-867D-4061-B1CE-F911F9F2395AQ27686870-FE56F561-C309-46FC-9BC2-15C3D99DE3C7Q28476822-35A82561-B043-4065-A827-15FF0C739852Q33613775-8674EF49-24F2-49B9-8E57-1C5D27BFBCB3Q33945171-DDA8FEFA-BD25-476F-9AFB-E5030885D07EQ34713094-E0669259-E73A-49D1-91D7-7AF2A4C328FCQ35026582-50C5AD02-B26B-471A-A17B-C2710D8B4529Q35065925-14ED8E2D-984E-4DC1-8F4F-D8C7ED4DF1A5Q35147189-7C9EED92-EB39-44B6-8D2F-6B8FF881C984Q35651599-BF1F6120-0C51-46BC-A503-51D58F47348EQ35693353-26CB2ECA-22DC-4618-B41A-AA1A38C8C761Q36145625-6D513D5E-9246-441F-B6A2-3EC55952B597Q36426953-3A6EB0F2-DC25-4DDE-A6B3-26E06F8C60C5Q36759898-97DF113B-45E1-4573-97E5-D127079C7159Q37473017-8D32125E-37FA-488A-A455-734E83E7D002Q37779319-D49A8902-DDE4-4770-A763-DBF7D5DE833AQ37779774-0006E0C0-3A61-44E3-8E10-2BA5F56DD2D4Q37803237-C3D62963-E858-4E1A-9826-9C34B1454942Q38081866-4C021A16-7386-414D-8D02-A21416B6A735Q38389563-8B9A7B4F-A067-4E4E-A6E3-AF9B9C1AE325Q38570500-6E65AD58-DF09-4D12-9DAC-64F281F01FE2Q39352071-1F43DC3B-CA5B-4917-95EA-1864E562AE24Q39511996-3423F417-9709-4737-B44D-9B43D832A927Q40536799-82051C71-536A-406D-93CE-813145025596Q42208301-07BFB9C9-4BCD-4F40-9FAB-FD47623C4F2CQ42260250-058CB8AF-0B39-434A-8BBB-9F44EB9D4664Q42787157-11F0B9F5-2D09-4942-A655-0388C43A69A8Q43227972-7B6A2A2A-221F-4DCE-801D-F2AF112BBB1DQ45923819-CE41A8EC-0B28-4BBE-BED6-A8B5F11EDF16
P2860
Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Switch from enfuvirtide to ral ...... a randomized open-label trial.
@en
Switch from enfuvirtide to ral ...... a randomized open-label trial.
@nl
type
label
Switch from enfuvirtide to ral ...... a randomized open-label trial.
@en
Switch from enfuvirtide to ral ...... a randomized open-label trial.
@nl
prefLabel
Switch from enfuvirtide to ral ...... a randomized open-label trial.
@en
Switch from enfuvirtide to ral ...... a randomized open-label trial.
@nl
P2093
P356
P1476
Switch from enfuvirtide to ral ...... a randomized open-label trial.
@en
P2093
Constance Delaugerre
EASIER ANRS 138 study group
François Raffi
Gilles Pialoux
Isabelle Charreau
Isabelle Madelaine-Chambrin
Jean-Luc Meynard
Jean-Michel Molina
Jean-Pierre Aboulker
Joséphine Braun
P304
P356
10.1086/605674
P407
P577
2009-10-01T00:00:00Z